Insights & Resources

New SEC-CFTC guidance clarifies how crypto assets are classified under U.S. law and when non‑security tokens may still fall under securities rules.

Private companies can simplify ASC 805 reporting for goodwill and intangibles. Explore ASU 2014-18 and 2014-02 alternatives, eligibility and key tips.

Understand key trading, valuation and compliance risks in repurchase agreements and TBA pools and how to strengthen oversight and internal controls.

AI adoption, digital asset volatility and evolving SEC exam priorities shaped Q4 2025. See what asset managers should watch in 2026.

Is your transaction a business combination or asset acquisition? Learn how ASC 805 guidance, the screen test and key differences shape reporting.

Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.

Get ahead of the curve by looking back at emerging trends in 2025 that are likely to impact health care valuation in 2026 and beyond. Download Weaver Insights now.

Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.

PET, CT and MRI volumes are accelerating. Learn what uneven imaging growth means for valuation and long-term planning.

Growth strategies in behavioral health are shifting. Learn how leaders can respond to industry headwinds and optimize performance effectively.

Key SEC 2026 exam priorities for RIAs and private funds, including fiduciary duty, AI oversight, cybersecurity and compliance expectations.

AI-driven growth, SEC reforms and shifting investor sentiment shaped Q3 2025. Weaver’s asset management team highlights key trends and risks.